Increased failure of budesonide MMX for ulcerative colitis during the COVID-19 pandemic: a population-based study.

IF 3.4 3区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Therapeutic Advances in Gastroenterology Pub Date : 2026-03-30 eCollection Date: 2026-01-01 DOI:10.1177/17562848261434442

Stephanie Coward, Karen J B Martins, Scott Klarenbach, Lawrence P Richer, Christopher Ma, Remo Panaccione, Cynthia H Seow, Karen Kroeker, Frank Hoentjen, Laura E Targownik, Gilaad G Kaplan

{"title":"Increased failure of budesonide MMX for ulcerative colitis during the COVID-19 pandemic: a population-based study.","authors":"Stephanie Coward, Karen J B Martins, Scott Klarenbach, Lawrence P Richer, Christopher Ma, Remo Panaccione, Cynthia H Seow, Karen Kroeker, Frank Hoentjen, Laura E Targownik, Gilaad G Kaplan","doi":"10.1177/17562848261434442","DOIUrl":null,"url":null,"abstract":"Background: Corticosteroids induce remission in ulcerative colitis (UC) but are associated with adverse effects, including prednisone ⩾20 mg/day associated with serious COVID-19 outcomes.Objectives: To evaluate the risk of rescue prednisone use following budesonide multimatrix system (MMX) initiation in newly diagnosed individuals with UC before and during the COVID-19 pandemic.Design: Population-based cohort study.Methods: We conducted a population-based study in Alberta, Canada, identifying adults with incident UC (2018-2022). Courses of budesonide MMX were examined for treatment failure, defined as prednisone rescue or inflammatory bowel disease-specific hospitalization within 90 days. Outcomes were compared between prepandemic (before April 2020) and pandemic periods using Cox proportional hazards models.Results: Among 269 dispensings of budesonide MMX (38 with multiple courses), 30.5% required rescue prednisone and 6.7% resulted in hospitalization. Budesonide MMX dispensing declined during the pandemic wherein, the hazard of prednisone rescue increased (HR 1.64; 95% CI: 1.01-2.67).Conclusion: Budesonide MMX was prescribed less frequently during the COVID-19 pandemic, with increased treatment failure, underscoring pandemic-related disruptions in UC management.","PeriodicalId":48770,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"19 ","pages":"17562848261434442"},"PeriodicalIF":3.4000,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13036333/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562848261434442","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Corticosteroids induce remission in ulcerative colitis (UC) but are associated with adverse effects, including prednisone ⩾20 mg/day associated with serious COVID-19 outcomes.

Objectives: To evaluate the risk of rescue prednisone use following budesonide multimatrix system (MMX) initiation in newly diagnosed individuals with UC before and during the COVID-19 pandemic.

Design: Population-based cohort study.

Methods: We conducted a population-based study in Alberta, Canada, identifying adults with incident UC (2018-2022). Courses of budesonide MMX were examined for treatment failure, defined as prednisone rescue or inflammatory bowel disease-specific hospitalization within 90 days. Outcomes were compared between prepandemic (before April 2020) and pandemic periods using Cox proportional hazards models.

Results: Among 269 dispensings of budesonide MMX (38 with multiple courses), 30.5% required rescue prednisone and 6.7% resulted in hospitalization. Budesonide MMX dispensing declined during the pandemic wherein, the hazard of prednisone rescue increased (HR 1.64; 95% CI: 1.01-2.67).

Conclusion: Budesonide MMX was prescribed less frequently during the COVID-19 pandemic, with increased treatment failure, underscoring pandemic-related disruptions in UC management.

查看原文本刊更多论文

在COVID-19大流行期间布地奈德MMX治疗溃疡性结肠炎的失败率增加：一项基于人群的研究

背景：皮质类固醇诱导溃疡性结肠炎（UC）缓解，但与不良反应相关，包括泼尼松小于20mg /天与严重的COVID-19结局相关。目的：评估新诊断的UC患者在COVID-19大流行之前和期间开始使用布地奈德多基质系统（MMX）后使用强的松的风险。设计：基于人群的队列研究。方法：我们在加拿大艾伯塔省进行了一项基于人群的研究，确定了2018-2022年发生UC的成年人。检查布地奈德MMX疗程的治疗失败，定义为90天内强的松抢救或炎症性肠病特异性住院。使用Cox比例风险模型比较了大流行前（2020年4月之前）和大流行期间的结果。结果：269个布地奈德MMX处方中（38个为多疗程），30.5%需要强的松抢救，6.7%导致住院。布地奈德MMX配药量在大流行期间下降，其中强的松抢救的危险增加（HR 1.64; 95% CI: 1.01-2.67）。结论：在COVID-19大流行期间，布地奈德MMX的处方频率较低，治疗失败率增加，强调了与大流行相关的UC管理中断。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Advances in Gastroenterology GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

6.70

自引率

2.40%

发文量

103

审稿时长

15 weeks

期刊介绍： Therapeutic Advances in Gastroenterology is an open access journal which delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of gastrointestinal and hepatic disorders. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in gastroenterology and related disciplines, providing an online forum for rapid dissemination of recent research and perspectives in this area. The editors welcome original research articles across all areas of gastroenterology and hepatology. The journal publishes original research articles and review articles primarily. Original research manuscripts may include laboratory, animal or human/clinical studies – all phases. Letters to the Editor and Case Reports will also be considered.